Studies of Alloantibody Effect on Skin Graft Survival in Mice

Kiyohiko DOHI, Toshimasa ASAHARA, Eiji ONO, Hiroshi YAHATA and Yasuhiko FUKUDA

The Second Department of Surgery, Hiroshima University School of Medicine, 1-2-3, Kasumi, Minami-ku, Hiroshima 734, Japan

(Received March 24, 1984)

Key words: Alloantibody, Immunosuppression, Mouse

ABSTRACT

Alloantisera (anti-donor and anti-recipient alloantiserum) were prepared by skin grafting followed four inoculations of $1 \times 10^7$ splenocytes.

These alloantisera were cytotoxic ($\times 64$) to target cells specifically.

Anti-recipient alloantiserum was effective on enhancing skin graft survival in mice as same as anti-donor alloantiserum, when administered on the operative day, second postoperative day and fourth postoperative day between 50-200 µl at one time.

(2) Lymphocyte cytotoxicity test

Lymphocyte cytotoxicity test was conducted in accordance with the NIH standard method.

Splenocytes as lymphocyte source were collected through a mesh, RBC in this cell suspension were removed by 0.84% NH₄Cl, and finally cell suspension was concentrated to 300-500 $\times 10^4$/ml.

Mixture of 1 µl of cell suspension and 1 µl of alloantiserum were placed in the well of microtest plate (Terasaki Tray) and left standing for 30 min at room temperature and then 5 µl of complement (fresh rat serum) was added to the well, and left standing for 60 min at room temperature.

They were stained by 5% eosin and fixed by formalin, and then % cell death was counted.

(3) Alloantiserum effect on skin graft survival

BALB/c mice were used as recipient and C3H/He mice as skin donor.

(a) Anti-donor alloantiserum effect on skin graft survival

C3H/He skin was grafted on the back of BALB/c mouse which was injected intraperitoneally with BALB/c anti-C3H/He alloantiserum three times, that is, on the operative day, second postoperative day, and fourth postoperative day. They consisted of three groups which
were administered 50 µl, 100 µl and 200 µl at one time.

(b) Anti-recipient alloantiserum effect on skin graft survival

C3H/He skin was grafted on the back of BALB/c mouse which was injected intraperitoneally with C3H/He anti-BALB/c alloantiserum three times, that is, on the operative day, second postoperative day, and fourth postoperative day. They consisted of three groups which were administered 50 µl, 100 µl and 200 µl at one time.

RESULTS

(1) Cytotoxic titer of alloantiserum

Cytotoxic titer (%) of C3H/He anti-BALB/c alloantiserum and BALB/c anti-C3H/He alloantiserum for BALB/c and C3H/He splenocytes are shown in Table 1.

<table>
<thead>
<tr>
<th>alloantiserum</th>
<th>target cell</th>
<th>× 4</th>
<th>×16</th>
<th>×64</th>
<th>×128</th>
<th>×256</th>
</tr>
</thead>
<tbody>
<tr>
<td>BALB/c anti-C3H/He (anti-donor)</td>
<td>BALB/c</td>
<td>5</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>10</td>
</tr>
<tr>
<td>C3H/He</td>
<td>90</td>
<td>90</td>
<td>50</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>C57BL/6</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>C3H/He anti-BALB/c (anti-recipient)</td>
<td>BALB/c</td>
<td>100</td>
<td>100</td>
<td>90</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>C3H/He</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>C57BL/6</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

C3H/He anti-BALB/c alloantiserum was cytotoxic to BALB/c cells at a cytotoxicity of ×64, but was not cytotoxic to C3H/He and C57BL/6 (H-2b) cells.

BALB/c anti-C3H/He alloantiserum was also cytotoxic to C3H/He cell at a cytotoxicity of ×64, but was not cytotoxic to BALB/c and C57BL/6 cells.

(2) Alloantiserum effect on skin graft survival

(a) Anti-donor alloantiserum effect on skin graft survival

Survival time of C3H/He skin grafts which were transplanted on three groups of BALB/c recipients was examined, that is, the first group was untreated, the second group was treated with BALB/c anti-C3H/He alloantiserum (anti-donor alloantiserum), and the third group was treated with C3H/He anti-BALB/c alloantiserum (anti-recipient alloantiserum).

The mean survival time (MST) of the graft of untreated BALB/c recipients used as control was 12.7±1.6 (S. D.) days.

In the group treated with anti-donor alloantiserum, MST was 17.9±1.9 days in 50 µl group, 18.2±1.9 days in 100 µl group, and 19.8±2.0 days in 200 µl group.

Their graft survival time was significantly longer than that of control group (P<0.001), the most prolonged survival was observed in 200 µl group.

(b) Anti-recipient alloantiserum effect on skin graft survival

In the group treated by anti-recipient alloantiserum, MST was 17.5±3.0 days in 50 µl group, 19.2±2.3 days in 100 µl group, and 18.8±4.3 days in 200 µl group. Their graft survival time was significantly longer than that of control group (P<0.001).

Survival was more prolonged in 100 µl group and 200 µl group than in 50 µl group.

The most prolonged time was 28 days in 200 µl group.

DISCUSSION

The immunosuppressants which have been employed during the last two decades in clinical transplantation are non-specific for immunosup-
Immunosuppressive Effect of Alloantibody

Preservative effects. They suppress not only transplant immunity but also infection protective mechanism and are sometimes lethal due to their side effects.

Therefore, the development of a more effective, safe and specific immunosuppressive therapy has been awaited. Anti-lymphocytic serum (ALS) has been used as a more specific immunosuppressive biological agent. ALS, being a heterologous serum, produces antibody in the recipient to decrease the effect of ALS. Symptoms resembling serum sickness develop in the recipient as side effects.

Many reports have been published in the literature on the clinical application of alloantiserum (alloantibody) which has a more specific effect and less side effects with the use of experimental models.

Among the alloantibodies, French, Jeekel and Steines have reported that anti-donor alloantibody is effective in allograft enhancement. However, anti-donor alloantibody is at the same an antibody to the graft and thus there is a risk that this antibody will induce hyperacute rejection. This is a serious problem point in the clinical application of this antibody.

On the other hand, in 1976 Davies et al. have reported that anti-recipient alloantibody has no effect on allograft enhancement in his model of skin graft in mice.

In view of the findings that alloantibody is specific as an immunosuppressant and has little side effects and that anti-recipient alloantibody has little danger of inducing hyperacute rejection, we have studied the allograft survival enhancement of this alloantibody.

C3H/He anti-BACB/c alloantisera and BACB/c anti-C3H/He alloserum were prepared by skin grafting followed by four weekly inoculations of $1 \times 10^7$ splenocytes.

These alloantisera were specific for immunogen cells and their cytotoxic titers were both $>64$. Before use, this alloantiserum was heat-inactivated and absorbed with RBC of the mouse used as immunogen to remove the antibody against RBC.

We examined the enhancing effect of these alloantisera on C3H/He skin transplanted BACB/c recipients when alloantiserum was administered on day 0, 2 and 4 after the transplantation.

In the groups administered anti-donor alloantisera, a significant enhancing effect on skin graft survival was observed in the groups administered a dose of 50 $\mu$l, 100 $\mu$l, and 200 $\mu$l at one time when compared to the control.

In these experiments, no case of hyperacute rejection was observed in the group that was administered anti-donor alloantiserum, but there is a possibility that hyperacute rejection may be induced in this group when the volume or schedule of alloantiserum administration is changed.

In the group which was administered anti-recipient alloantiserum at a dose of 50 $\mu$l, 100 $\mu$l, and 200 $\mu$l, the skin graft survival was significantly prolonged when compared to that of the control.

These enhancing effects on skin graft survival were all the same for anti-donor alloantiserum and anti-recipient alloantiserum when administered in the same volume and schedule.

There has been no report in the literature to the effect that anti-recipient alloantiserum can enhance allograft survival.

Davies et al. have reported that skin graft survival was not enhanced with anti-recipient alloantiserum in mice. It is assumed that our anti-recipient alloantiserum was effective in enhancing skin graft survival, because the administered dose at one time was 5–20 times greater than that given by Davies et al. Both our anti-donor alloantiserum and anti-recipient alloantiserum showed the same enhancing effect on the skin graft survival of mice.

In particular, anti-recipient alloantiserum which does not induce hyperacute rejection is assumed to be more effective, safe and specific immunosuppressant.

Through in vitro studies, the mechanism of immunosuppressive effect of anti-recipient alloantisera will be pursued.

REFERENCE


